|
J Biol Chem, Vol. 274, Issue 12, 7929-7935, March 19, 1999
A Short Loop on the ALK-2 and ALK-4 Activin Receptors Regulates
Signaling Specificity but Cannot Account for All Their Effects on Early
Xenopus Development
Niall A.
Armes,
Katherine A.
Neal, and
James C.
Smith
From the Division of Developmental Biology, National Institute for
Medical Research, The Ridgeway, Mill Hill,
London NW7 1AA, United Kingdom
Activin, a member of the transforming growth
factor (TGF- ) superfamily, signals through a heteromeric complex
of type I and type II serine-threonine kinase receptors. The two
activin type I receptors previously identified, ALK-2 (ActR-I) and
ALK-4 (ActR-IB), have distinct effects on gene expression,
differentiation and morphogenesis in the Xenopus animal cap
assay. ALK-4 reproduces the effects of activin treatment including the
dose-dependent induction of progressively more
dorso-anterior mesodermal and endodermal markers, whereas ALK-2 induces
only ventral mesodermal markers and counteracts the effects of ALK-4.
To identify regions of the receptors that determine signaling
specificity we have generated chimeras of the constitutively active
ALK-2 and ALK-4 receptors (termed ALK-2* and ALK-4*). The effects of
these chimeric receptors on gene expression and morphogenetic movements
implicate the loop between kinase subdomains IV and V in mediating the
strong dorsal gene-inducing properties of ALK-4*; when the seven amino acids comprising this loop are transferred from ALK-4* to ALK-2*, the
resulting chimeric receptor is capable of inducing the expression of
dorsal-specific genes. In contrast, when the equivalent region of
ALK-2* is transferred to the ALK-4* backbone it cannot effectively counteract the dorsalizing effects of ALK-4*, suggesting that other
regions of type I receptors are also involved in determining signal specificity.
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Itoh, M. Thorikay, M. Kowanetz, A. Moustakas, F. Itoh, C.-H. Heldin, and P. ten Dijke
Elucidation of Smad Requirement in Transforming Growth Factor-beta Type I Receptor-induced Responses
J. Biol. Chem.,
January 31, 2003;
278(6):
3751 - 3761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Valcourt, J. Gouttenoire, A. Moustakas, D. Herbage, and F. Mallein-Gerin
Functions of Transforming Growth Factor-beta Family Type I Receptors and Smad Proteins in the Hypertrophic Maturation and Osteoblastic Differentiation of Chondrocytes
J. Biol. Chem.,
September 6, 2002;
277(37):
33545 - 33558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-G. Chen, H. M. Lui, S.-L. Lin, J. M. Lee, and S.-Y. Ying
Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin
Experimental Biology and Medicine,
February 1, 2002;
227(2):
75 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fujii, K. Takeda, T. Imamura, H. Aoki, T. K. Sampath, S. Enomoto, M. Kawabata, M. Kato, H. Ichijo, and K. Miyazono
Roles of Bone Morphogenetic Protein Type I Receptors and Smad Proteins in Osteoblast and Chondroblast Differentiation
Mol. Biol. Cell,
November 1, 1999;
10(11):
3801 - 3813.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|